Clinical trials: Proteinuria, open to volunteers
Diabetes
Urinary Vitamin C Loss in Diabetic Subjects
Several studies have reported that diabetic subjects have lower plasma vitamin C concentrations than non-diabetic subjects. Although urinary vitamin C loss in diabetic subjects was reported to be increased in two studies, these…
- Trial name
- NCT00071526
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pediatric Hereditary Kidney Diseases
The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children
This study is a multicenter, randomized controlled crossover trial aimed to evaluate the efficacy and safety of dapagliflozin in the treatment of hereditary kidney disease with proteinuria in children
- Trial name
- NCT06890143
- Testing
- Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Children's Hospital of Fudan University
Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD)
Relationship Between Insulin Dose and Complications in Type 1 Diabetes
The goal of this observational study is to better understand how the amount of insulin people with type 1 diabetes are using relates to blood glucose control and the risk of complications.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD), Severe Albuminuria, Estimated Glomerular Filtration Rate (eGFR)
- Trial name
- iDose-EDC (NCT07911033)
- Testing
- Routine/prescribed exogenous insulin dose
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Rachel Miller
Kidney Transplant, Chronic Kidney Disease
Empagliflozin Treatment in Kidney Transplant Recipients
Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging.
- Trial name
- SEKTR (NCT06013865)
- Testing
- Empagliflozin
- Where
- 5 sites in United States
- Volunteers
- 264 people
- Sponsor
- VA Office of Research and Development
Chronic Kidney Disease, Proteinuria
A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines
The goal of this study is to establish whether use of a digital intervention can improve adherence and alignment with the Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) 2024 Guidelines.
- Conditions
- Chronic Kidney Disease, Proteinuria, Blood Pressure Control, Congenital Anomalies of the Kidneys and Urinary Tract
- Trial name
- NCT07561957
- Testing
- Use of an electronic digital Application
- Where
- 2 sites in Ireland
- Volunteers
- 80 people
- Sponsor
- St. James's Hospital, Ireland
Paroxysmal Nocturnal Hemoglobinuria
The International PNH Interest Group PNH Registry
The aim of this International PNH Interest Group (IPIG) registry is to develop an international database to prospectively collect data on patients with PNH covering clinical outcomes, patient reported outcomes (PROs), and…
- Trial name
- NCT06524726
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- International PNH Interest Group
Chronic Kidney Disease, Proteinuria
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine.
- Conditions
- Chronic Kidney Disease, Proteinuria, Children
- Trial name
- FIONA OLE (NCT05457283)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 151 sites in United States, Argentina and 30 more
- Volunteers
- 100 people
- Sponsor
- Bayer
IgA Nephropathy
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
immunoglobulin A (IgA) nephropathy (Berger disease) is the most frequent primary glomerulonephritis worldwide. This disease accounts for about 5% of the causes of end stage renal disease in France, representing a major public…
- Trial name
- QUIgAN (NCT06350630)
- Testing
- Hydroxychloroquine Oral Tablet
- Where
- 8 sites in France
- Volunteers
- 334 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
IgA Nephropathy
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient…
- Trial name
- NCT07541287
- Testing
- JADE101
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Jade Biosciences, Inc.
Chronic Kidney Diseases, Type 2 Diabetes Mellitus
Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa
Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality. The prevalence of CKD is increasing worldwide and is assumed to also dramatically increase in Sub-Saharan Africa (SSA).
- Conditions
- Chronic Kidney Diseases, Type 2 Diabetes Mellitus, Arterial Hypertension, Obesity
- Trial name
- RenalTWO (NCT05881447)
- Where
- Tanzania
- Volunteers
- 1,200 people
- Sponsor
- Swiss Tropical & Public Health Institute
Nephrotic Syndrome Steroid-Dependent, Nephrotic Syndrome Steroid-Resistant
Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study
Idiopathic Nephrotic Syndrome is a rare disease of the kidneys, which typically affects children. For most affected children there is the need of a prolonged treatment with drugs reducing the activity of the immune system, also…
- Conditions
- Nephrotic Syndrome Steroid-Dependent, Nephrotic Syndrome Steroid-Resistant, Nephrotic Syndrome in Children, Glomerulonephritis
- Trial name
- PRECISE (NCT06792448)
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy
A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
This is a post-marketing surveillance study conducted as part of the Risk Management Plan (RMP) for South Korea, to evaluate the safety and effectiveness of iptacopan in real-world clinical settings for the treatment of either…
- Trial name
- NCT07416162
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Focal Segmental Glomerulosclerosis, Proteinuria
ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank
Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, fluid retention and impaired…
- Conditions
- Focal Segmental Glomerulosclerosis, Proteinuria, Nephrotic Syndrome, Nephrotic Syndrome Steroid-Resistant
- Trial name
- NCT06162546
- Testing
- Registry
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Christoph Aufricht
Referral and Consultation, Glomerulonephritis
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
The purpose of the study is to evaluate prospectively the impact of an electronic health record (EHR) alert on primary care providers' (PCP) referral to Nephrology of Geisinger patients with high risk signs (blood and protein in…
- Conditions
- Referral and Consultation, Glomerulonephritis, Hematuria, Proteinuria
- Trial name
- NCT07431931
- Testing
- Electronic Health Record alert
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Geisinger Clinic
Acute Kidney Injury
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
Acute kidney disease (AKD) happens between 7 and 90 days after an initial kidney injury (AKI). This period is crucial because it can determine whether the condition worsens into chronic kidney disease (CKD).
- Trial name
- ESS-AKD (NCT06528405)
- Testing
- dapagliflozin, Other anti-diabetic drug or no anti-diabetic drug, empagliflozin
- Where
- Taiwan
- Volunteers
- 264 people
- Sponsor
- National Taiwan University Hospital
Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
This study is an exploratory, randomized, double-blind, multicenter, placebo-controlled study with repeated doses of AP1189. The study population will consist of patients with idiopathic membranous nephropathy (iMN) and severe…
- Trial name
- NCT04456816
- Testing
- 100 mg AP1189
- Where
- Denmark
- Volunteers
- 23 people
- Sponsor
- SynAct Pharma Aps
Obesity and Diabetes Mellitus, Type 2, Albuminuria
Obesity-Related Indices and Albuminuria in Type 2 Diabetes
This cross-sectional study aims to evaluate obesity-related indices and albuminuria levels in patients with type 2 diabetes mellitus.
- Trial name
- NCT07922694
- Volunteers
- 349 people
- Sponsor
- Assiut University
Proteinuric Renal Disease, Proteinuric Kidney Disease
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors
- Conditions
- Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
- Trial name
- NCT07224776
- Testing
- sparsentan, No sparsentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Primary Immunoglobulin A Nephropathy (IgAN)
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in primary immunoglobulin A…
- Trial name
- NCT06994845
- Testing
- iptacopan
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes, Proteinuria
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)
The overall aim of the project is to elucidate the primary bio-psycho-social (BPS) risk factors for albuminuria in youth with type 2 diabetes (T2D) and the mechanisms by which they cause renal injury. The Study aims include: 1.
- Conditions
- Type 2 Diabetes, Proteinuria, Stress, Nephropathy
- Trial name
- iCARE (NCT02818192)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- University of Manitoba